Elsevier supports Pistoia Alliance in accelerating safe and responsible AI adoption in drug discovery

Elsevier, a global leader in information and analytics, and provider of data and AI-enabled decision support tools for innovation in life sciences, today announced a commitment to support global not-for-profit organization The Pistoia Alliance, which advocates for greater collaboration in the life sciences.

The commitment sets out to address common challenges in AI adoption facing the pharmaceutical and research community. Elsevier will provide expertise through a joint program of events for Pistoia’s 200+ member organizations, which include top pharmaceutical, biotech, healthcare and R&D organizations as well as regulators. Elsevier has supported the Alliance for more than a decade, helping to equip organizations with the capabilities and tools needed to harness the full potential of AI for effective and efficient drug discovery, in a safe and ethical manner.

The announcement follows Elsevier's recent Attitudes to AI report, which found widespread willingness among corporate researchers to use AI tools, but also concerns about associated risks, such as misinformation, critical errors, and gaps in critical thinking. These concerns are echoed in The Pistoia Alliance’s recent Lab of the Future Report 新しいタブ／ウィンドウで開く, which also uncovered demand for more educational resources, such as ontologies training – an area of specialism for SciBite, an Elsevier company.

Drawing on these insights, Elsevier has identified the following five key areas for advancing greater AI adoption in drug discovery:

1. Securing trustworthy data – Robust data sourcing drives accurate and effective research results.

2. Structuring data to reveal insights – Leveraging the FAIR data principles and ontologies transforms complex scientific data into accessible and contextualized knowledge structured for AI.

3. Transparent AI – Retaining human oversight and implementing Retrieval-Augmented Generation (RAG) architecture overcomes the issue of 'black box' AI systems and drives transparency and credibility in AI outcomes.

4. Unified governance – Research professionals and legislators must be aligned to effectively navigate AI regulations, such as the new EU AI Act.

5. Bridging the skills gap – Many organizations still cite the lack of internal skills as an AI barrier, accessing a combination of scientific expertise with data science and tech knowledge.

Upcoming events addressing these areas include:

• Webinar: Rapid Biomedical Insight Discovery with AI 新しいタブ／ウィンドウで開く, featuring Ivana Kotevic, VP Product for Corporate Life Sciences at Elsevier, and Guy Kingham, Senior Director for Strategy at Elsevier’s Life Sciences business (Nov 4^th).

• AI workshop featuring multiple SciBite and Elsevier spokespeople: Democratizing Data in Life Sciences: The Role of LLMs (Nov 12th).

• Keynote address on AI in drug discovery by Mirit Eldor, Managing Director, Life Sciences Solutions, Elsevier, at The Pistoia Alliance Annual Conference in Philadelphia 新しいタブ／ウィンドウで開く (Nov 12^th).

• Presentation on Evolution and Evaluation of Scientific search and discovery by Mark Sheehan, Vice President, Data Science Life Science Solutions, Elsevier, at The Pistoia Alliance Annual Conference in Philadelphia 新しいタブ／ウィンドウで開く (Nov 13^th).

• Webinar: Assisting Ontology Development with LLMs 新しいタブ／ウィンドウで開く, featuring Simon Jupp, Head of Semantic Technology, SciBite (Nov 21^st).

Mirit Eldor, Managing Director, Life Sciences Solutions, Elsevier, said:

The Pistoia Alliance continues to be the ideal forum for productive collaboration. It is clear that coming together to share learnings and best practices can help all navigate the challenges of overcoming data barriers in the life sciences. Ultimately, our goal is to remove barriers so that we can realize the full potential of AI in accelerating the development of safe and effective therapies. We're delighted to continue playing our part in this ecosystem, building on Elsevier’s long history of data expertise to further support the Alliance’s members and the broader R&D community.

Dr. Becky Upton, President of the Pistoia Alliance, said:

Elsevier and Pistoia Alliance’s recent surveys find there is a drive among researchers to adopt AI. Yet, data from both studies also show that life science organizations are still grappling with challenges ranging from access to data to building trust in AI tools. Elsevier has been a valued member of the Alliance since 2015 and has actively contributed to impactful initiatives that are shaping the future of our industry. The Pistoia Alliance will continue to work with its members to provide tangible deliverables to the life sciences community to help them address these AI challenges.

About Elsevier

As a global leader in scientific information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making with innovative solutions based on trusted, evidence-based content and advanced AI-enabled digital technologies.

We have supported the work of our research and healthcare communities for more than 140 years. Our 9,500 employees around the world, including 2,500 technologists, are dedicated to supporting researchers, librarians, academic leaders, funders, governments, R&D-intensive companies, doctors, nurses, future healthcare professionals and educators in their critical work. Our 2,900 scientific journals and iconic reference books include the foremost titles in their fields, including Cell Press, The Lancet and Gray’s Anatomy.

Together with the Elsevier Foundation 新しいタブ／ウィンドウで開く, we work in partnership with the communities we serve to advance inclusion and diversity in science, research and healthcare in developing countries and around the world.

Elsevier is part of RELX 新しいタブ／ウィンドウで開く, a global provider of information-based analytics and decision tools for professional and business customers. For more information on our work, digital solutions and content, visit www.elsevier.com.

About Pistoia Alliance

The Pistoia Alliance 新しいタブ／ウィンドウで開く is a global, not-for-profit members’ organization made up of life science companies, technology and service providers, publishers, and academic groups working to lower barriers to innovation in life science and healthcare R&D. It was conceived in 2007 and incorporated in 2009 by representatives of AstraZeneca, GSK, Novartis, and Pfizer who met at a conference in Pistoia, Italy. Its projects transform R&D through pre-competitive collaboration. It overcomes common R&D obstacles by identifying the root causes, developing standards and best practices, sharing pre-competitive data and knowledge, and implementing technology pilots. There are currently over 200 member companies; members collaborate on projects that generate significant value for the worldwide life sciences R&D community, using the Pistoia Alliance’s proven framework for open innovation.